MediciNova, Inc. filings document a clinical-stage biopharmaceutical issuer developing MN-166 and MN-001 across neurological, inflammatory, fibrotic, and metabolic disease programs. Annual and event filings describe reported financial results, including preliminary unaudited results furnished through a Japanese Kessan Tanshin, and securities registration materials for common stock offerings.
Proxy and 8-K filings cover MediciNova's Delaware corporate governance, director elections, executive compensation, equity awards, stockholder voting results, and Nasdaq-listed common stock. The filing record also provides formal disclosure around capital structure, risk factors, material events, and governance matters tied to the company's drug-development business.
MediciNova, Inc. (MNOV) reports that 3D Investment Partners Pte. Ltd., acting as investment manager to 3D Opportunity Master Fund, indirectly sold 640,000 shares on September 25, 2026, at a reported $2.70 per share; the reported price was converted from Japanese yen. The indirect position following the transaction was 4,862,047 shares. The form reports no Rule 10b5-1 plan.
MEDICINOVA INC (MNOV) reporting persons 3D Investment Partners Pte. Ltd. and 3D Opportunity Master Fund may be deemed beneficial owners of up to 4,862,047 shares, approximately 9.9%, as of September 25, 2026. The percentage is based on 49,221,246 shares outstanding as of August 11, 2026. On September 25, 2026, the reporting persons sold 640,000 shares in a private sale to a third-party financial institution for JPY 425 (approximately US$2.7) per share and ceased to have beneficial ownership over the shares sold.
The reporting persons also disclosed cash-settled total return swaps providing economic exposure to 456,637 notional shares, approximately 0.9% of outstanding shares. The swaps do not provide voting or disposition power and cannot be converted into MNOV shares. Their observer appointment right under the Shareholder Rights Agreement lapsed in 2024, and they no longer have an observer appointed to attend board meetings.
MediciNova, Inc. (MNOV) amended its lease, originally dated July 20, 2021, with Irvine Company LLC through an amendment with Newport Gateway Office LLC. The amendment extends the lease end date from January 31, 2027, to April 30, 2030, unless sooner terminated under the lease. Rent increases take effect on February 1, 2027.
MediciNova, Inc. (MNOV) has elected to terminate its Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). The agreement, originally dated July 30, 2025, had allowed MediciNova, on a discretionary basis, to issue and sell up to $30.0 million of common stock to Yorkville. Under this facility, the company sold a total of 175,000 shares at prices between $1.39 and $1.40 per share, receiving aggregate proceeds of $0.2 million. The termination, made via a formal Notice of Termination dated August 31, 2026, will become effective on September 8, 2026. At termination, there were no outstanding borrowings, advance notices, or shares remaining to be issued under the agreement, and no fees are payable by either MediciNova or Yorkville in connection with ending the facility.
MediciNova, Inc. (MNOV) entered into new executive employment agreements with President & CEO Yuichi Iwaki and Chief Medical Officer Kazuko Matsuda, replacing their prior arrangements. The agreements set base salaries, bonus opportunities, and detailed severance protections tied to both ordinary terminations and Change in Control events.
Dr. Iwaki’s package includes a higher cash-and-equity severance multiple than in non‑Change in Control cases, while Dr. Matsuda’s agreement provides somewhat lower but similar protections. Both receive COBRA coverage for specified periods and 100% acceleration of unvested equity upon qualifying terminations in connection with a Change in Control. The agreements are at-will, governed by Delaware law, and include non‑solicitation, Section 280G cutback, and Section 409A compliance provisions.
MediciNova, Inc. reported Q2 2026 revenue of $458,439, all from research services supporting an ALS study for Mayo Foundation. For the first six months of 2026, revenue was $645,423. Net loss narrowed to $2.3 million in Q2 and $4.9 million year-to-date.
Research, development and patents expense declined to $1.0 million in Q2 and $2.3 million for the first half, mainly from lower MN‑166 and MN‑001 clinical costs, while general and administrative expenses rose to $1.8 million in Q2 and $3.4 million year-to-date due to higher professional fees and stock-based compensation.
Cash and cash equivalents were $25.4 million at June 30, 2026, with working capital of $23.0 million. Management states this is sufficient to fund operations at least through November 2027, though the company expects continued losses as it advances MN‑166 and MN‑001 and may seek additional equity financing under existing shelf arrangements.
MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. Following this grant, Nagao holds 44,500 stock options directly.
The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the company. This is a compensation-related award rather than an open-market purchase or sale.
MediciNova Inc. director Nicole Lemerond received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. They vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, contingent on her continued service with the company.
MediciNova Inc. director Carolyn Beaver received a stock option grant covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. The award vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, subject to her continued service with the company. After this grant, she holds 44,500 derivative securities (options). This is a compensation-related award rather than an open-market share purchase or sale.
MediciNova, Inc. reported results from its 2026 annual meeting of stockholders held on June 23, 2026. As of the April 24, 2026 record date, the company had 49,221,246 shares of common stock outstanding, and 29,774,819 shares were represented in person or by proxy, establishing a quorum.
Two director nominees, Hikedi Nagao and Nicole Lemerond, each received more votes "For" than "Against," with substantial broker non-votes recorded. Three additional proposals also showed more "For" than "Against" votes, based on totals of 26,697,794 vs. 1,911,245; 22,156,922 vs. 6,432,457; and 22,656,038 vs. 5,805,893, respectively.